Full-Time
Vice President
Sales
Manifold AI
51-200 employees
AI-powered platform for clinical research workflows
Compensation Overview
$210k - $255k/yr
Cambridge, MA, USA
Hybrid
Hybrid work in Cambridge, Massachusetts, with regular in-person collaboration.
 Sales & Account Management (1) |
|---|
Get referred to Manifold AI
See people who can refer or advise you
- 10+ years of experience selling complex enterprise software solutions, with a strong track record in enterprise deal cycles.
- Demonstrated success building and scaling a sales motion, ideally as an early sales hire or sales leader at a materially growing company.
- Firsthand experience being part of a strong sales team, sales culture, and results-oriented environment, with the ability to explain the methodology, cadence, and management practices that made it work.
- Experience operating in both high-velocity and enterprise sales motions and building a team capable of both.
- A proven track record of meeting and exceeding sales quotas.
- Ability to build trusted-advisor relationships with stakeholders ranging from C-level executives to end users through consultative selling.
- Proficiency in team-based selling and in determining when to involve solutions engineering, scientific solutions, or product team members.
- Ability to construct sales approaches, sales enablement, territory alignment, and a sales team in an early-stage environment.
- Experience selling alongside cloud hyperscaler partnerships such as Amazon Web Services and Snowflake as a channel.
- Strong written and verbal communication and presentation skills.
- A strong analytical and quantitative mindset.
- Ability to operate with limited direct supervision in an ambiguous, fast-moving environment.
- Willingness to travel as required.
- Own and execute the sales motion into target markets, driving pipeline generation and net new bookings against an annual quota.
- Anchor the team on a defined sales methodology and a consistent, stage-based sales process for qualifying, forecasting, and managing the pipeline.
- Develop a deep understanding of the company vision, mission, and platform and use it to generate interest among prospects and customers.
- Develop and execute territory, account, and opportunity sales approaches grounded in a consultative, trusted-advisor approach.
- Directly lead a team of enterprise sellers, velocity sellers, and business development representatives as the team scales.
- Leverage pre-sales solutions engineering and scientific solutions team members in a team-based selling approach.
- Feed customer and prospect learnings into the sales approach and positioning.
- Coordinate with professional services, product, and marketing teams, surface new requirements, and help evolve the go-to-market message.
- Motivate and inspire the sales team and broader teammates through customer-focused leadership.
- Experience selling into life sciences and health care is strongly preferred.
Manifold AI provides an AI-powered platform that accelerates clinical research for life sciences, especially cancer centers and rare-disease studies. The platform harmonizes multimodal data from electronic health records, genomics, and medical imaging into a single secure, analysis-ready workspace and offers AI-powered cohort exploration, data engineering, bioinformatics, secure collaboration, and study management. Researchers interact with complex data through user-friendly interfaces and natural language queries, without writing code, and the system can be implemented in months to speed from data collection to insights. Its focus on integrated data harmonization, built-in AI tools, and streamlined workflows differentiates it from bespoke internal solutions and fragmented tools, with a goal to shorten clinical research timelines and expand collaboration with research institutions.
Company Size
51-200
Company Stage
Series B
Total Funding
$40.5M
Headquarters
Newton, Massachusetts
Founded
2016
Get referred to Manifold AI
See people who can refer or advise you
Simplify's Take
What believers are saying
- Manifold closed an $18 million Series B on December 18, 2025, bringing total funding to $40 million.
- April 2026 partnerships with Savant Bio and Intelliseq expand AI-ready structured clinical datasets.
- June 2026 Foundation Medicine deployment and Agent OS launch show product expansion into production workflows.
What critics are saying
- Manifold’s revenue depends on a few regulated lighthouse accounts, especially Foundation Medicine and UVA.
- Agent OS opened limited evaluation slots in June 2026, signaling constrained sales capacity.
- Incumbents like Broad, AWS, and Anthropic can replicate governed biomedical workflows by 2027.
What makes Manifold AI unique
- Manifold pairs governed research environments with AI agents for multimodal life-sciences workflows.
- Broad Institute collaboration in January 2025 validates Manifold’s infrastructure inside elite biomedical research.
- Foundation Medicine, UVA, and Intelliseq embed Manifold into proprietary clinical and genomic workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Parental Leave
Commuter Benefits
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 8%2 year growth
↑ 5%Manifold and Savant Bio partner to accelerate creation of high quality, ai-ready biological datasets. April 8, 2026 NEWTON, MA and NEW YORK, NY - Wednesday, April 8 - Manifold, the AI platform for life sciences, and Savant Bio, a health data infrastructure company, today announced a technology partnership to enable automated, high-fidelity clinical data abstraction within Manifold's governed platform. The collaboration enables life sciences organizations and health systems to convert unstructured clinical records - including physician notes, pathology reports, and imaging narratives - into structured, analysis-ready datasets directly within Manifold's secure, governed environment. By bringing abstraction, analytics, and multimodal data together in one environment, the partnership aims to accelerate research, evidence generation, and clinical development. Despite advances in interoperability and the growing adoption of real-world data, more than 80% of clinically meaningful information remains locked in unstructured formats - including physician notes, lab reports, imaging narratives, and genomics - leaving the majority of healthcare data underutilized. As a result, R&D teams often spend months assembling and harmonizing datasets before analysis can begin, delaying discovery and limiting real-world evidence generation. Savant's LLM-powered abstraction engine combines advanced language models, domain-specific quality controls, and human-in-the-loop validation to extract clinically meaningful variables such as disease staging, treatment sequencing, biomarker status, and response assessments. These outputs are designed to integrate with Manifold's platform, where they can be analyzed alongside genomic, imaging, claims, and other multimodal data. "Life sciences teams shouldn't have to choose between greater data richness and faster time to insight," said Vinay Seth Mohta, CEO of Manifold. "This partnership is intended to help researchers move from raw clinical records to high-quality multimodal datasets that are legible to AI agents." "High-quality research depends on data that is structured, traceable, and fit for purpose," said Brian Moriarty, Co-Founder of Savant Bio. "By integrating our abstraction capabilities directly into Manifold's research environment, we're ensuring that clinically meaningful information is captured with provenance and delivered in a form ready for analysis." The partnership will initially focus on select datasets and high-priority use cases, with abstraction outputs integrated into Manifold's Trusted Research Environment. Over time, it may expand to support configurable workflows and the creation of standardized, governed data assets reusable across studies, sites, and industry partners. Across the drug development lifecycle, the collaboration will support translational research, clinical development, and health economics and outcomes research by enabling structured phenotypic and clinical annotations, informing trial feasibility and external control arms, and powering comparative effectiveness and market access analyses. By enabling health systems and life sciences organizations to work from shared, governed datasets within a common analytical environment, the partnership aims to strengthen collaboration, improve data utility, and accelerate the translation of real-world data into actionable insights. About Manifold Manifold is the AI platform for life sciences, accelerating life-changing medicines to patients. Its products speed up workflows in areas from target identification and clinical development to market access and precision medicine in the clinic, while maintaining the governance life sciences requires. Global companies and premier research institutions use Manifold to operate faster and more effectively. Backed by leading investors including Reach Capital, TQ Ventures, Calibrate Ventures, SilverArc Capital, and Industry Ventures, Manifold serves tens of thousands of users across hundreds of organizations globally. Learn more at manifold.ai About Savant Bio Savant is transforming how healthcare and life sciences organizations unlock the value trapped in unstructured medical data. Its clinical data abstraction platform combines advanced large language models with domain-specific quality controls to convert free-text clinical records into structured, analysis-ready data - efficiently, accurately, and at scale. Savant has supported programs across more than 30 therapeutic areas to date and partners with leading institutions across healthcare, life sciences, and research to deliver sharper insights and better outcomes. Learn more at savantbio.com.
Manifold raises $18M in Series B financing to advance AI for life sciences. NEW YORK - Manifold, a Newton, Massachusetts-based tech company, said on Thursday that it has raised $18 million in a Series B funding round to advance its artificial intelligence platform for life sciences. To read the full story...
Manifold, an AI platform for life sciences, has raised $18 million in a Series B round led by Reach Capital, with participation from SilverArc Capital, Industry Ventures and existing investors TQ Ventures and Calibrate Ventures. The funding brings total capital raised to $40 million. The company is building vertical AI infrastructure for biopharma companies and medical centres, supporting workflows from target identification to clinical development and precision medicine. Its platform handles multi-entity collaboration, multimodal biomedical data and governance requirements specific to the $2 trillion life sciences industry. Manifold operates Terra, serving thousands of researchers across hundreds of organisations globally. Customers include Foundation Medicine and the University of Virginia. The funding will expand its Agent OS, deepen collaboration infrastructure and scale its data ecosystem.
Manifold raises $18 million Series B to define vertical AI for life sciences and accelerate life-changing medicines to patients. The new funding cements Manifold's leadership in the $2 trillion life sciences market, powering next-generation AI workflows from early discovery through precision care. Newton, MA (December 18, 2025) - Manifold, the AI platform for life sciences, today announced an $18 million Series B funding round led by Reach Capital, with participation from SilverArc Capital, Industry Ventures, and existing investors TQ Ventures and Calibrate Ventures. The round brings Manifold's total capital raised to $40 million and positions the company as the emerging category leader in vertical AI for life sciences. Manifold's platform is transforming how biopharma companies and medical centers accelerate workflows from target identification to clinical development, market access, and precision medicine in the clinic. Defining vertical AI for life sciences. Vertical AI platforms are transforming productivity in major industries - legal services, financial services, customer experience, and more - with support for domain-specific data, workflows, and governance that go much deeper than horizontal platforms. In life sciences, a $2 trillion industry where productivity directly impacts patient outcomes, Manifold is defining this category. This field requires purpose-built infrastructure for multi-entity collaboration, multimodal biomedical data, and workflows that span from bench to clinic. Manifold's platform is purpose-built for this complexity. "In every industry, companies that combine agentic AI and domain-specific context will transform productivity. Customers are seeking proven partners in this transformation. We believe Manifold is the emerging category leader for vertical AI in life sciences," said Jennifer Carolan, Partner at Reach Capital. Accelerating Agent development and the data flywheel. The new funding will enable Manifold to advance its platform with capabilities that materially improve life sciences productivity: * Expand the Agent OS: Advancing how AI agents operate on multimodal biomedical data, use scientific tools, and leverage institutional context to accelerate work, from biomarker development and model validation through trial design and real-world evidence generation. * Deepen collaboration infrastructure: Extending features that enable teams to share analyses, reuse context, and work across organizational boundaries with appropriate governance and data sovereignty. * Scale the data ecosystem: Constructing novel datasets becomes easier as more organizations join, compounding value for all participants while maintaining data ownership and governance. Strategic milestones and growing momentum. Over the past year, Manifold has achieved significant milestones that demonstrate both strong product-market fit and compounding network effects: * Workflow breadth: AI agents which can be tailored to specific datasets and tools across dozens of workflows - from cohort identification and biomarker discovery to treatment pathway analysis and outcomes research. * Enterprise momentum: A growing customer base including leading companies like Foundation Medicine and academic centers like the University of Virginia. * Strategic collaborations: Deepening strategic collaborations with the Broad Institute, AWS, and Anthropic which strengthen both scientific and technical capabilities and go-to-market reach. * Terra operation: As an operator of Terra, Manifold now serves thousands of researchers across hundreds of life sciences organizations globally. "Our customers and partners are pushing the boundaries of what's possible in life sciences, and we're honored to build alongside them. This funding accelerates our shared goal to transform productivity in life sciences and get life-changing medicines to patients faster," said Vinay Seth Mohta, CEO, Manifold. For an inside look at the vision driving Manifold's next phase of growth, visit the CEO blog. About Manifold. Manifold is the AI platform for life sciences, accelerating life-changing medicines to patients. Its products speed up workflows in areas from target identification and clinical development to market access and precision medicine in the clinic, while maintaining the governance life sciences requires. Global companies and premier research institutions use Manifold to operate faster and more effectively. Backed by leading investors including Reach Capital, TQ Ventures, Calibrate Ventures, SilverArc Capital, and Industry Ventures, Manifold serves tens of thousands of users across hundreds of organizations globally.
What You Should Know:– The Broad Institute of MIT and Harvard is collaborating with Manifold, a leader in AI-powered research infrastructure, to develop a next-generation platform for biomedical research.– The strategic partnership aims to enhance data analysis, secure sharing, and global collaboration, empowering scientists worldwide to accelerate discovery.Manifold: Accelerating Biomedical Research with AIFounded in 2016, Manifold’s AI-powered platform streamlines biomedical research by automating manual tasks in data collection, organization, governance, and analysis. This allows researchers to focus on scientific discovery, unlocking the full potential of their data without technical barriers.Building on the success of Terra, a trusted platform for large-scale data analysis, the new platform will address the evolving needs of modern life sciences research. It will incorporate advanced capabilities while upholding Terra’s core values of secure sharing, global collaboration, and responsible data stewardship.Enhanced Capabilities for a New Era of ResearchThe new platform will introduce several key enhancements:Bring Your Own Cloud: Offers flexibility for researchers to work within their organization’s cloud strategy.Offers flexibility for researchers to work within their organization’s cloud strategy. Enhanced Scalability: Accommodates the growing volume and complexity of biomedical data.Accommodates the growing volume and complexity of biomedical data. Data Harmonization: Seamlessly integrates diverse datasets while ensuring data ownership and control.Seamlessly integrates diverse datasets while ensuring data ownership and control. Purpose-Built AI Agents: Provides advanced capabilities like natural language search, cohort building, and automated analysis.Provides advanced capabilities like natural language search, cohort building, and automated analysis